ClinicalTrials.gg
Active, not recruitingNCT07713290Updated Jul 20, 2026

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

A Phase 1 interventional study of GKL-006 Injection and Transarterial chemoembolization (TACE) in Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Cancer, sponsored by Beijing Gene Key Life Technology Co., Ltd. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Beijing Gene Key Life Technology Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Apr 2025, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,310 studies in Carcinoma, Hepatocellular with a site in China — 486 open to participants now, 558 under way, 70 of them phase 3. Carcinoma, Hepatocellular · China.

Enrollment
996th of 1,034
6 · median 78
Started
2025
with 121 others
Phase 1
138 of 1,310
60 open now
Primary completion
2026-11
later than 294 of 557 live
Registered
1,267th of 1,310
by date

Among the 1,310 studies in Carcinoma, Hepatocellular with a site in China, this one is the 996th largest by enrollment of the 1,034 interventional ones that give a count, is one of 122 that started in 2025, is one of 138 in phase 1, reaches primary completion later than 294 of the 557 other live ones, and was the 1,267th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

486 of the 1,310 studies in Carcinoma, Hepatocellular with a site in China are open now. Recruiting first, the newest first:

481 more — sign in →

All 486 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,310 studies in Carcinoma, Hepatocellular with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.

Read the detailed description

This Phase 1b study evaluates multiple doses of GKL-006 Injection in participants with unresectable hepatocellular carcinoma (HCC).

The purpose of this study is to evaluate the safety and tolerability of multiple doses of GKL-006 Injection. The study will also evaluate pharmacokinetic and pharmacodynamic characteristics of GKL-006 Injection, how it affects the body, and whether it shows preliminary anti-tumor activity in patients with HCC according to mRECIST.

Participants will receive GKL-006 Injection and TACE treatment. They will be followed for adverse events, tumor response, disease progression, subsequent anti-tumor therapy, and survival.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Cancer

Keywords

  • GKL-006
  • Unresectable hepatocellular carcinoma
  • HCC
  • Immunotherapy
  • Cell therapy
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participates in the study and provides written .
  • Has pathologically, cytologically, or radiologically confirmed unresectable hepatocellular carcinoma.
  • Has CNLC stage II to IIIa disease.
  • Has not received transarterial chemoembolization within 6 months before screening.
  • Has at least one according to .
  • class A or B.
  • performance status of 0 - 2.
  • Has not received radiotherapy, chemotherapy, targeted therapy, or therapy within 4 weeks before screening.

Exclusion criteria

Exclusion Criteria:

  • Has a known allergy to the product or related components, including human serum albumin.
  • Has another incurable within 5 years before screening or concurrently, except for cured basal cell carcinoma of the skin, carcinoma in situ, or breast cancer without recurrence for more than 3 years after radical surgery.
  • Has a previous diagnosis of mixed or rare histologic subtypes, including fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepatocellular-cholangiocarcinoma.
  • Has major vascular invasion on imaging.
  • Has hepatic encephalopathy within 4 weeks before screening.
  • Has clinically symptomatic ascites or pleural effusion requiring drainage, or has undergone thoracic or abdominal fluid drainage within 2 weeks before enrollment.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    GKL-006 Injection Plus TACE

    Participants will receive GKL-006 Injection in combination with TACE according to the study protocol.

    Drug: GKL-006 Injection · Procedure: Transarterial chemoembolization (TACE)

Interventions

  • An iNKT cell therapy

    Also known as: GKL-006, iNKT Cells

  • ProcedureTransarterial chemoembolization (TACE)

    A standard locoregional therapy for hepatocellular carcinoma

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Treatment-Related Adverse Events and Safety/Tolerability Risks

    Treatment-related adverse events and laboratory abnormalities will be assessed and graded according to NCI CTCAE v5.0. Safety and tolerability risks include study treatment-related adverse events or laboratory abnormalities occurring.

    Time frame: From the start of study treatment through 14 days after the fourth treatment; treatment-related adverse events will continue to be assessed according to the study protocol.

Secondary outcomes

  1. Progression-Free Survival (PFS) Based on mRECIST

    PFS defined as the time from enrollment to disease progression assessed according to mRECIST or death from any cause, whichever occurs first.

    Time frame: From enrollment to the first documented disease progression or death from any cause, up to 18 months.

  2. Overall Survival

    The time from enrollment to death from any cause.

    Time frame: From enrollment until death or the end of study follow-up, approximatelly 30 months.

  3. One-Year Overall Survival Rate (1Y-OS)

    The proportion of participants who are alive 1 year after enrollment.

    Time frame: 1 year after enrollment.

  4. Time to Progression (TTP)

    The time from enrollment to the first documented disease progression according to mRECIST.

    Time frame: From enrollment until the first documented disease progression or the end of study follow-up, up to 18 months.

  5. Objective Response Rate (ORR)

    The rate of participants with a best overall response of complete response (CR) or partial response (PR) according to mRECIST.

    Time frame: From enrollment until disease progression, initiation of new anti-tumor therapy, death, or the end of study follow-up, up to 18 months.

  6. Duration of Response (DOR) Based on mRECIST

    The time from the first documented CR or PR according to mRECIST to disease progression or death from any cause, whichever occurs first.

    Time frame: From first documented response until disease progression, death, or the end of study follow-up, up to 18 months.

  7. Disease Control Rate (DCR) Based on mRECIST

    The rate of participants with a best overall response of CR, PR, or stable disease (SD) according to mRECIST.

    Time frame: From enrollment until disease progression, initiation of new anti-tumor therapy, death, or the end of study follow-up, up to 18 months.

  8. Pharmacokinetic characterization of maximum observed plasma concentration (Cmax) of GKL-006

    Maximum observed plasma concentration of GKL-006 following intravenous administration according to protocol.

    Time frame: From 60 minutes before the first dose through 60 days.

  9. Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax) of GKL-006

    Time to reach the maximum observed plasma concentration of GKL-006 following a single intravenous administration.

    Time frame: From 60 minutes before the first dose through 60 days.

  10. Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC) of GKL-006

    Area under the plasma concentration-time curve of GKL-006 following a single intravenous administration.

    Time frame: From 60 minutes before the first dose through 60 days.

  11. Pharmacokinetic characterization of terminal elimination half-life (t½) of GKL-006

    Terminal elimination half-life of GKL-006 calculated from plasma concentration-time data following a single intravenous administration.

    Time frame: From 60 minutes before the first dose through 60 days.

  12. Pharmacodynamic Biomarkers of NK cells

    Immune cell subsets

    Time frame: From 60 minutes before the first dose through 60 days.

  13. Pharmacodynamic Biomarkers of T cells

    Immune cell subsets

    Time frame: From 60 minutes before the first dose through 60 days.

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 19 months is below that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jul 20, 2026
StartActual
Apr 3, 2025
Primary completionEst.
Nov 12, 2026
CompletionEst.
Feb 28, 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07713290
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Apr 3, 2025
Primary completion
Nov 12, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jul 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GKL-006

Start the discussion